| Company* (Country; Symbol) | Company | Type/Product Area | Terms/Details (Date) |
| FluGen Inc.* | Ratio Inc.* | Exclusive rights agreement to a vaccine delivery technology being commercialized by Ratio | FluGen expects to begin preclinical testing with its cell-based trivalent influenzavaccines using the disposable micro-device from Ratio this year, with plans tosubmit an investigational new drug application in the second half of 2010(3/24) |
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
